Dentsply Sirona: weak sales, but profit recovery and dealer expansion
Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.
The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.
Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.
Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.
Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.
This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.
Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.
Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.